摘要
目的探讨子宫颈外用红色诺卡氏菌细胞壁骨架(Nr-CWS)治疗宫颈高危型人乳头瘤病毒(HPV)感染的安全性和有效性。方法选择2019年1月至2021年1月在广州市第一人民医院妇产科门诊就诊经分子病理检测确诊感染HPV高危亚型且液基细胞学检查排除宫颈恶性病变的患者206例,年龄(37.50±8.14)岁,采用Nr-CWS外敷子宫颈治疗10 d为1个疗程,治疗结束后3个月评估药物疗效。结果经过Nr-CWS治疗后高危亚型HPV总清除率为79.13%(163/206);治疗HPV16、HPV18及合并单个或多个高危亚型HPV感染总有效率分别为84.31%(43/51)、82.61%(19/23)及83.33%(15/18)、87.50%(7/8),各组之间差异无统计学意义(P>0.05);对治疗其他单个或多个高危亚型HPV感染总有效率为73.13%(49/67)和71.43%(20/28)。结论子宫颈外用Nr-CWS治疗宫颈高危型HPV感染是有效和可耐受的,尤其对感染HPV16、HPV18型或合并其他亚型HPV患者可适时选择药物Nr-CWS治疗。
Objective To investigate the safety and efficacy of Nocardia rubra cell wall skeleton(Nr-CWS)in the treatment of cervical high-risk human papillomavirus(HPV)infection.Methods From January 2019 to January 2021,206 patients who were diagnosed to be infected with high-risk subtypes of HPV by molecular pathological examination and excluded cervical malignant lesions by liquid-based cytology in the Obstetrics and Gynecology Clinic,Guangzhou First People's Hospital were selected,with an age of(37.50±8.14)years old.Nr-CWS was applied to the cervix for 10 days as a course,and the drug efficacy was evaluated 3 months after the end of treatment.Results After treatment with Nr-CWS,the total clearance rate of high-risk subtype HPV was 79.13%(163/206);the total effective rates of HPV16,HPV18,and combined with single or multiple high-risk subtypes of HPV infection were 84.31%(43/51),82.61%(19/23),83.33%(15/18),and 87.50%(7/8)respectively,and there was no statistically significant difference among all the groups(P>0.05).The total effective rates for the treatment of other single or multiple high-risk subtypes of HPV infection were 73.13%(49/67)and 71.43%(20/28).Conclusion Nr-CWS is effective and tolerable in the treatment of cervical high-risk HPV infection,especially for patients infected with HPV16,HPV18 or combined with other subtypes of HPV.
作者
石丽琼
杨宇
岑春华
邱少燕
Shi Liqiong;Yang Yu;Cen Chunhua;Qiu Shaoyan(Department of Gynecology,Guangzhou First People's Hospital,Guangzhou 510100,China)
出处
《国际医药卫生导报》
2021年第24期3844-3846,共3页
International Medicine and Health Guidance News
